In collaboration with the clinical team, SGS has actively pursued innovative biomarker assay development and validation. To complement our range of immunoassays, we are now offering LC-MS/MS technology that has enabled us to extend our portfolio to include more biomarkers such as steroidal and hormonal substances in the low picogram range. We have also invested in the field of multiplexing, using the bead-based suspension and electro-chemiluminescence-based platforms to offer robust immunoassays for application in clinical trials.
At SGS, we have over 20 years’ experience in biomarker assay development services and analysis and we operate out of two of our own GLP laboratories. With 125 specialized staff, this makes our bioanalytical facility one of the largest in Europe. Pharma and biotech companies of all sizes choose us as their preferred bioanalytical partner because we have the expertise to develop assays de novo – and support large-scale routine sample analysis.
Whether for testing efficacy or safety of drugs in development, our biomarker bioanalytical services cover a range of therapeutic areas to include:
- Central nervous system (CNS)
- Metabolic disorders
- Thyroid disease
- Sexual health
- Bone disease
- Allergy and respiratory